BeiGene, Ltd. Price, Chart & Factor Exposure
Free Data & Analytics AccessLatest earnings: November 5, 2026 results vs estimates
BeiGene, Ltd. Forecast
BeiGene, Ltd. short-term momentum is positive (up over 3 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term BUY signal. The long-term trend is strongly positive (8 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 34.3% a year, a typical one-standard-deviation range is 353.60–389.52 over a week, 334.76–408.36 over a month and 244.09–499.03 over a year. (Signals as of 1 Nov 2026.)
BeiGene, Ltd. Price Chart
BeiGene, Ltd. Factors
YoY −91.8%
YoY −17.6%
YoY −22.3%
YoY −74.4%
YoY −20.3%
YoY +136.1%
YoY +1,120.2%
YoY +9.5%
YoY +53.5%
YoY −62.9%
YoY +48.4%
YoY +47.1%
YoY —
YoY −20.1%
YoY 0.0%
YoY +10.0%
BeiGene, Ltd. fundamentals: income statement, balance sheet & cash flow
BeiGene, Ltd. reported revenue of $5.34bn and net income of $286.9m in FY2025, the year ended 31 December 2025 — revenue up 40.2% and net income up 144.5% on the prior year. Free cash flow was $941.7m. These figures are as reported in the filings, not restated: 13 fiscal years and 51 quarters of history, back to December 2013. 44 FINRA short-interest settlements are published alongside them, back to January 2025.
| USD millions | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 |
| Revenue | 5,343.0 | 3,810.2 | 2,458.8 | 1,415.9 | 1,176.3 |
| Cost of revenue | 668.5 | 594.1 | 379.9 | 286.5 | 164.9 |
| Gross profit | 4,674.5 | 3,216.2 | 2,078.9 | 1,129.4 | 1,011.4 |
| Research & development | 2,145.9 | 1,953.3 | 1,778.6 | 1,640.5 | 1,459.2 |
| Selling, general & admin. | 2,081.5 | 1,831.1 | 1,508.0 | 1,278.6 | 990.1 |
| Operating income | 447.1 | -568.2 | -1,207.7 | -1,789.7 | -1,438.7 |
| EBITDA | 616.8 | -361.2 | -738.2 | -1,894.8 | -1,392.1 |
| Interest expense | 58.2 | 21.8 | 4.4 | 52.5 | — |
| Pre-tax income | 416.9 | -533.0 | -825.8 | -1,961.0 | -1,438.6 |
| Income tax | 129.9 | 111.8 | 55.9 | 42.8 | 19.2 |
| Net income | 286.9 | -644.8 | -881.7 | -2,003.8 | -1,457.8 |
Download BeiGene, Ltd. fundamentals
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.ONC.NASDAQ&statement=all&freq=a&format=csv&years=10
Figures in USD, statements as filed and FINRA consolidated short interest. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic. Short interest is the consolidated FINRA figure for the settlement date shown, published seven to eight business days later.
Research on BeiGene, Ltd.
Explore MacroFinance macro & markets research and analysis.
BeiGene, Ltd. Trading Strategies
58 backtested tactical asset allocation strategies hold SPY (US market) or XLV (Health Care sector), the closest tradable exposure to BeiGene, Ltd.; 28 of them are invested now. Strategies currently invested are listed first.
| Strategy | Style | Rebalance | Now in SPY, XLV | CAGR | Sharpe | Max DD |
|---|---|---|---|---|---|---|
| Tactical Permanent Portfolio | Conservative | Monthly | Premium · upgrade to view | |||
| Zakamulin and Giner's Optimal Trend Following | Moderate | Monthly | Premium · upgrade to view | |||
| Movement Capital's Composite Strategy | Moderate | Monthly | Premium · upgrade to view | |||
| Harry Browne's Permanent Portfolio | Conservative | Monthly | 25% | 7.0% | 0.96 | -17.2% |
| Keller and Van Putten's Flexible Asset Allocation | Moderate | Monthly | Premium · upgrade to view | |||
| Ned Davis' Three Way Model | Moderate | Monthly | Premium · upgrade to view | |||
| 60_40 Benchmark | Moderate | Monthly | 60% | 8.2% | 0.93 | -29.5% |
| Dick Stoken's Active Combined Asset (ACA) - Monthly Trading | Moderate | Monthly | Premium · upgrade to view | |||
| PortfolioCharts' Golden Butterfly | Moderate | Monthly | 20% | 7.4% | 0.91 | -18.0% |
| US Cross-Asset Momentum | Moderate | Monthly | Premium · upgrade to view | |||
Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.
From creators
- P4 Demo Momentum by admin
- strategyx by admin
Statistical Distribution of Returns
PlusHow BeiGene, Ltd.’s returns are distributed — and how they change in a given market regime.
Regime filters
| Market/Macro | Indicator | Criteria | Value | And (for Between) | Action |
|---|
No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.
| Statistic | All periods | Matching |
|---|
About BeiGene, Ltd. (United States)
BeiGene, Ltd. is a listed security in the United States. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).
Last updated: November 22, 2026
More on BeiGene, Ltd.
Frequently asked questions
What is BeiGene, Ltd.?
What is the latest BeiGene, Ltd. price?
Is BeiGene, Ltd. in an uptrend?
How volatile is BeiGene, Ltd.?
What factors affect BeiGene, Ltd.?
Which trading strategies trade BeiGene, Ltd.?
How are BeiGene, Ltd. returns analysed?
Where can I download free BeiGene, Ltd. historical data?
Free BeiGene, Ltd. historical data (last 10 years)
Browse or instantly download the last 10 years of BeiGene, Ltd. daily price history. A free account unlocks the full history, an Excel export with factors, and API access.
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.ONC.NASDAQ&format=csv&years=10
| Date | Close |
|---|---|
| 2026-11-20 | 390.94 |
| 2026-11-19 | 399.7 |
| 2026-11-18 | 403.6 |
| 2026-11-17 | 413.26 |
| 2026-11-16 | 411.29 |
| 2026-11-13 | 416.54 |
| 2026-11-12 | 415.96 |
| 2026-11-11 | 419.98 |
| 2026-11-10 | 424 |
| 2026-11-09 | 417.33 |
About this stock
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. The company has a agreement with U.S. government to expand access to innovative cancer medicines. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.
See how this market's returns behaved when a factor was in a given state, for example when Momentum was strong or bond yields were above 4%, and compare that with all periods.
Reading the chart
- Each bar is a return bucket; its height is the share of periods that landed there.
- All periods: every return in the date range.
- Matching periods: only the periods where all your filters were true. If orange shifts right of the grey, returns were better in that regime.
- Each period's return is the return over the following day, week or month (set by Timeframe), measured from the day the factor was read, so there is no look-ahead.
Adding a filter
- Factor: grouped the same way as the Factors section on this page (Quantitative, Country, Sector, …). Locked factors are listed but greyed out.
- Criteria: greater (>), greater or equal (≥), equal (=), smaller or equal (≤), smaller (<) or between two values.
- Value: depends on the factor.
- Momentum and Trend are signals from −1 to +1, picked as −100 to +100 in steps of 25.
- Mean Reversion is a z-score of price against its 250-day mean, picked in σ from −3 to +3.
- Everything else is a number you type. The line under the box shows the latest reading and its typical range over the last 10 years.
Add several filters to combine conditions; a period must pass every one. Narrow the window with the From/To dates or the 1Y / 5Y / 10Y / MAX buttons; Clear resets filters and dates.
Return statistics
- Unfiltered vs Filtered: all periods vs matching periods.
- Average return, Std dev and Sharpe are annualised (252 days, 52 weeks, 12 months, 6 two-month periods, 4 quarters).
- Maximum drawdown compounds non-overlapping periods; in the Filtered column it assumes you held only while the condition was true.
- Min, 25th percentile, median, 75th percentile and max are per period, not annualised.